As the health care industry becomes more institutionalized and as major for profit corporations begin to increast their market share, there exists the real danger of isolating patients enrolled in Health Maintenance Organizations form high quality clinical cancer trials. This would represent a loss botyh for the individual patients as well as society. This application is designed to integrate clinical cancer trials within the largest HMO in California, Kaiser Permanente. The San Diego region of Kaiser Permanente provides total health care for 290,000 patients and Kaiser Permanents, state wide, cares for over 10% of the population. The San Diego Kaiser Permanents has for several years been quited active in national groups studying cancer treatment such as Cancer and Acute Leukemia Group B and National Surgical Adjuvant Project for Breast and Bowel Cancer. The added resources provided by a Community Clinical Oncology Program would enormously expand the capability to provide a wide variety of clinical cancer trials to our medical, pediatric and gynecologic cancer pateints. The centralized administration of cancer treatment would also enahcne physician education and improve the overall quality of cancer care delivered to all of our patients. In addition, the large volume of patients followed in our Health Appraisal Clinic constitutes an ideal population to evaluate for cancer control issues. By demonstrating that involvement in high quality cancer treatment and cancer control trials under the auspices of a CCOP both enhances patient care without added expense and improves physician competence and motivation, a role model may be established that can be expanded to involve other regions within our Health Maintenance Organization.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Kaiser Foundation Research Institute
United States
Zip Code
Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8
Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6
Dressler, Lynn G; Berry, Donald A; Broadwater, Gloria et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-97
Byrd, John C; Rai, Kanti; Peterson, Bercedis L et al. (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53
Muss, Hyman B; Woolf, Susan; Berry, Donald et al. (2005) Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 293:1073-81
Ahles, Tim A; Herndon 2nd, James E; Small, Eric J et al. (2004) Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer 101:2202-8
Graziano, S L; Tatum, A; Herndon 2nd, J E et al. (2001) Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 33:115-23
Stone, R M; Berg, D T; George, S L et al. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-53
Hayes, D F; Yamauchi, H; Broadwater, G et al. (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-11